Workflow
Inventus Reports Average Grade and Thickness of 3.84 gpt Gold Over 1.82 Metres from Grade Control Drilling at Its 007 North 5,000-Tonne Bulk Sample Site
Globenewswire· 2025-06-04 11:00
Highlights The grade control drilling program for the first of two bulk sample sites is now completed (Figure 1), and assays for the first site, 007 North, are reported in Table 1. The initial grade control drilling program commenced on May 5 to define approximately 15,000 tonnes of a planned 45,000-tonne bulk sample program. A total of 68 holes for 623 metres were completed on May 23. Of those holes, 33 were completed at the 007 North site outlining approximately 5,000 tonnes of material. The recent drilli ...
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Globenewswire· 2025-06-04 11:00
The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the "Equity Rule") by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neuro ...
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
Globenewswire· 2025-06-04 11:00
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from GLP-1 drugs is fueling significant demand for endoscopic alternatives designed to restore health rather than manage disease BURLINGTON, Mass. and SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), ...
Essential Utilities: A Dividend Champion On Sale
Seeking Alpha· 2025-06-04 11:00
The supermarket has different aisles (i.e., produce, bakery, dairy, etc.), whereas the stock market has investment options across 11 GICS sectors. The stock market is comparable to a supermarket. This article was co-produced with Kody Kester. And this offer includes a 2-Week FREE TRIAL plus my FREE book. Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with ...
Eldorado Gold Announces Election of Directors and Results from the 2025 Annual and Special Meeting of Shareholders
Globenewswire· 2025-06-04 11:00
VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation ("Eldorado" or "the Company") is pleased to announce that all director nominees, as listed in the Management Proxy Circular dated April 15, 2025, were elected as directors of Eldorado at the Company's Annual and Special Meeting of Shareholders (the "Meeting") held on June 3, 2025. "On behalf of the Board, we would like to thank our shareholders for their continued support. With our transformative Skouries copper-gold pr ...
Dividend payment ex-date of AS Tallinna Vesi
Globenewswire· 2025-06-04 11:00
Taavi Gröön AS Tallinna Vesi CFO (+372) 62 62 200 taavi.groon@tvesi.ee Proceeding from the above, the ex-date is 09 June 2025. From that date the new owner of the shares is not entitled to dividends for the year 2024. AS Tallinna Vesi will pay dividend 0.53 euro per share. Dividends are paid out to shareholders on 17 June 2025. AS Tallinna Vesi (trading code TVE1T, ISIN code EE3100026436) will close the list of shareholders for dividend payment on 10 June 2025 at the end of the working day of the settlement ...
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Globenewswire· 2025-06-04 11:00
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites Forward-Looking Statements "We are pleased by the initial findings from the SAD trial that demonstrated a favorable safety profile for DT- 216P2 and support its advancement in the MAD FA patient trial. We are surprised by FDA's n ...
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire News Room· 2025-06-04 11:00
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8- week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clin ...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
Prnewswire· 2025-06-04 11:00
- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel, June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPl ...
Check-Cap claims BMO’s Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
Globenewswire· 2025-06-04 11:00
Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ: CHEK) ("Check- Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairm ...